Please use this identifier to cite or link to this item:
Title: Matched cohort study on the efficacy of tocilizumab in patients with COVID-19
Author: Rodríguez Molinero, Alejandro
Pérez López, Carlos
Gálvez Barrón, César
Miñarro Alonso, Antonio
Macho, Oscar
López, Gabriela F.
Robles, Maria Teresa
Dapena, María Dolores
Martínez, Sergi
Rodriguez, Ezequiel
Collado Pérez, Isabel
COVID-19 research group of CSAPG
Keywords: SARS-CoV-2
Issue Date: 5-Jan-2021
Publisher: Elsevier B.V.
Abstract: Background: Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID-19 and lung involvement. Methods: Observational study on a cohort of 418 patients, admitted to three county hospitals in Catalonia (Spain). Patients admitted consecutively were included and followed until discharge or up to 30 days of admission. A sub-cohort of patients treated with tocilizumab and a sub-cohort of control patients were identified, matched by a large number of risk factors and clinical variables. Sub-cohorts were also matched by the number of other treatments for COVID-19 that patients received. Increment in SAFI (inspired oxygen fraction / saturation) 48 h after the start of treatment, and time to discharge, were the primary outcomes. Mortality, which was a secondary outcome, was analyzed in the total cohort, by using logistic regression models, adjusted by confounders. Results: There were 96 patients treated with tocilizumab. Of them, 22 patients could be matched with an equivalent number of control patients. The increment in SAFI from baseline to 48 h of treatment, was not significantly different between groups (tocilizumab: −0.04; control: 0.09; p = 0.636). Also, no difference in time to discharge was found between the two sub-cohorts (logrank test: p = 0.472). The logistic regression models, did not show an effect of tocilizumab on mortality (OR 0.99; p = 0.990). Conclusions: We did not find a clinical benefit associated with the use tocilizumab, in terms of respiratory function at 48 h of treatment, or time to discharge.
Note: Reproducció del document publicat a:
It is part of: One Health, 2021, vol. 12
Related resource:
ISSN: 2352-7714
Appears in Collections:Articles publicats en revistes (Genètica, Microbiologia i Estadística)

Files in This Item:
File Description SizeFormat 
706771.pdf1.45 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons